Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Financing › Details

Elitech–PAI Partners: investment, 201705– acquisition of Elitech Group by PAI Partners from Ergon Capital Partners

 

Period Period 2017-05-11
  Successor Elitech–Bruker: investment, 202312– acquisition €870m in cash of Elitech Group from PAI Partners SIGNED Put Option Letter
Organisations Money taker Elitech France SAS
  Group Elitech (Group)
  Money source PAI Partners SAS
  Group PAI Partners (Group)
Products Product in vitro diagnostics (IVD)
  Product 2 private equity
Person Person Drago, Stefano (PAI Partners 202312 Partner)
     

PAI Partners SAS. (5/11/17). "Press Release: PAI Partners Enters into Exclusive Negotiations for the Acquisition of ELITech". Paris.

PAI Partners, a leading European private equity firm, announces today that it has entered into exclusive negotiations with Ergon Capital Partners, a pan-European mid-market private equity investment company, for the acquisition of ELITech Group (“ELITech”), a manufacturer of specialty in-vitro diagnostics (“IVD”) equipment and reagents.

ELITech is a leading mid-sized fully integrated diagnostics platform developing equipment and reagents with strong positions in niche and growing sub-segments of molecular diagnostics, microbiology and clinical chemistry. ELITech has developed an attractive razor-razorblade model through the placement of diagnostic instruments which provide a resilient revenue stream from reagents, consumables, spare parts and services.

Stefano Drago, Partner at PAI Partners, commented: “Over the past years, PAI has invested significant time and resources in the labs and diagnostics space. We believe IVD is an attractive segment and are delighted to be partnering with an outstanding management team led by Christoph Gauer. ELITech is a unique asset and we look forward to working with the team to successfully implement its growth strategy in the coming years.”

Wolfgang de Limburg, Managing Partner of Ergon, commented: “This successful investment is consistent with Ergon’s long-term philosophy and approach to value creation. Over the life of this investment, Ergon supported ELITech’s focused strategy, significant R&D programs, geographical expansion, add-on acquisitions, and ambition for operational excellence. We trust that ELITech and its outstanding management team will succeed in further creating value in the future and we are convinced that PAI will be an excellent partner for the company’s next phase of growth.”

The French employee works councils of ELITech will be consulted in respect of the transaction and completion of the transaction would be subject to regulatory approval and other customary conditions precedent.


Media contacts

PAI Partners
Greenbrook Communications: Matthieu Roussellier / Annabel Clay
Tel.: +44 20 7952 2000

DGM: Michel Calzaroni / Olivier Labesse / Hugues Schmitt
Tel.: +33 1 40 70 11 89

Ergon
John Mansvelt
Tel.: +32 2 213 60 93

   
Record changed: 2024-01-09

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Elitech (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px




» top